Subcutaneous Ocrelizumab Not Inferior to IV Infusion

(MedPage Today) -- MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III OCARINA II trial showed...
Source: MedPage Today Neurology - Category: Neurology Source Type: news